TABLE 1.
Nomenclature used by the authors | ApoEVs types according to sizes | Original cell | Recipient cell | Diseases/experimental effect | Mechanism | Role of vesicles | References |
ApoBDs | Mix of ApoBDs and ApoMVs | Endothelial cells | Endothelial progenitor cells | Promote proliferation | Unclear | Unclear | Hristov et al., 2004 |
ApoBDs | Unclear | Cardiomyocytes | Cardiomyocyte precursors | Chronic post-infarction heart failure | Promote SC proliferation and differentiation | miRNA transfer? | Tyukavin et al., 2015 |
ApoBDs | ApoBDs | Macrophages | Epithelial cells | Promote proliferation | MiR-221 miR-222 | miRNA transfer | Zhu et al., 2017 |
ApoBDs | Mix of ApoBDs and ApoMVs | Endothelial cells | Vascular cells | Atherosclerosis | Induced CXCL12-dependent vascular protection | miRNA transfer | Zernecke et al., 2009 |
ApoBDs | Mix of ApoBDs and ApoMVs | Epithelial stem cells | Epithelial stem cells | Promote proliferation and division | Activate Wnt8a | mRNA transfer | Brock et al., 2019 |
ApoBDs | ApoBDs | BMSCs | BMSCs | Osteopenia | Activate the Wnt/β-catenin pathway | miRNA transfer | Liu et al., 2018 |
ApoBDs | Mix of ApoBDs and ApoMVs | MSCs | Endothelial cells | Myocardial infarction | Regulate autophagy | Active lysosome function | Liu et al., 2020 |
CRK-MVs | ApoMVs | podocytes | Epithelial cells | Renal repair | Induce compensatory proliferation | Paracrine mediators? | Bussolati and Camussi, 2017 |
MOC- ApoBDs | ApoBDs | Osteoclasts | Pre-osteoblasts | Bone remodeling | Activate PI3K/AKT/mTOR/S6K signaling | RANK activator | Ma et al., 2019 |
ApoBDs, apoptotic bodies; SCs, stem cells; BMSCs, bone mesenchymal stem cells; MSCs, mesenchymal stem cells; PI3K, phosphoinositide 3-kinase; AKT, AKT Ser–Thr kinase; S6K, ribosomal protein S6 kinase; RANK, nuclear factor kappa B.